F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.54 EUR 2.67% Market Closed
Market Cap: 570.4m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fluidigm Corp
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Gross Profit
$63.6m
CAGR 3-Years
-10%
CAGR 5-Years
-1%
CAGR 10-Years
0%
Thermo Fisher Scientific Inc
NYSE:TMO
Gross Profit
$17.3B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Gross Profit
$12.6B
CAGR 3-Years
-9%
CAGR 5-Years
8%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Gross Profit
$2.2B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Gross Profit
$3.6B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
16%
IQVIA Holdings Inc
NYSE:IQV
Gross Profit
$5.4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
14%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
569.7m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
1.08 EUR
Overvaluation 30%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Gross Profit?
Gross Profit
63.6m USD

Based on the financial report for Jun 30, 2024, Fluidigm Corp's Gross Profit amounts to 63.6m USD.

What is Fluidigm Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
0%

Over the last year, the Gross Profit growth was 37%. The average annual Gross Profit growth rates for Fluidigm Corp have been -10% over the past three years , -1% over the past five years .

Back to Top